Patents Assigned to Celera Corporation
  • GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20140072957
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: February 11, 2013
    Publication date: March 13, 2014
    Applicant: Celera Corporation
    Inventors: Hongjin HUANG, Michele CARGILL
  • GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20140072550
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: June 27, 2013
    Publication date: March 13, 2014
    Applicant: CELERA CORPORATION
    Inventors: Olga IAKOUBOVA, James J. DEVLIN, Carmen TONG, Charles ROWLAND
  • POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT
    Publication number: 20140024623
    Abstract: The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Application
    Filed: January 15, 2013
    Publication date: January 23, 2014
    Applicants: Celera Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Methods and compositions for treating and diagnosing diseases
    Patent number: 8632987
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: January 21, 2014
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Bruno Domon, Candy Lee
  • Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof
    Patent number: 8614058
    Abstract: The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 24, 2013
    Assignee: Celera Corporation
    Inventors: Kit Lau, Alice Wang
  • METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES
    Publication number: 20130315915
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: April 30, 2013
    Publication date: November 28, 2013
    Applicant: Celera Corporation
    Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
  • Composite metastasis score with weighted coefficients for predicting breast cancer metastasis, and uses thereof
    Patent number: 8557525
    Abstract: The present invention relates to a composite metastasis score (“cMS”) based on expression of a 14-gene molecular signature (referred to as a metastasis score, or “MS”) in combination with progesterone receptor (PR) expression that is useful for predicting breast cancer metastasis. In preferred embodiments, the cMS is determined by applying weighted coefficients to MS and PR. The present invention provides methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information for predicting risk of breast cancer metastasis, among other embodiments.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: October 15, 2013
    Assignee: Celera Corporation
    Inventors: Alice Wang, Robert J. Lagier, Charles M. Rowland
  • Cancer targets and uses thereof
    Patent number: 8524238
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 3, 2013
    Assignee: Celera Corporation
    Inventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
  • GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHDOS OF DETECTION AND USES THEREOF
    Publication number: 20130216551
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: December 12, 2012
    Publication date: August 22, 2013
    Applicant: CELERA CORPORATION
    Inventor: CELERA CORPORATION
  • GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20130209486
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: October 22, 2012
    Publication date: August 15, 2013
    Applicant: CELERA CORPORATION
    Inventor: Celera Corporation
  • Methods and compositions for treating diseases targeting maba
    Patent number: 8507213
    Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: August 13, 2013
    Assignee: Celera Corporation
    Inventors: Candy Lee, Steve Ruben, Bruno Domon, Charles E. Birse
  • Methods and compositions for diagnosing and treating diseases
    Patent number: 8486392
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: July 16, 2013
    Assignee: Celera Corporation
    Inventors: Steve Ruben, Paul Moore, Tao He, Candy N. Lee, Karen Van Orden
  • METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES
    Publication number: 20130177566
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: November 6, 2012
    Publication date: July 11, 2013
    Applicant: CELERA CORPORATION
    Inventor: Celera Corporation
  • COLON DISEASE TARGETS AND USES THEREOF
    Publication number: 20130111613
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: September 17, 2012
    Publication date: May 2, 2013
    Applicant: CELERA CORPORATION
    Inventors: Yeounjin KIM, Tao HE, Steve RUBEN
  • CANCER TARGETS AND USES THEREOF
    Publication number: 20130078253
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 28, 2013
    Applicant: CELERA CORPORATION
    Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
  • GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20130078627
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: July 23, 2012
    Publication date: March 28, 2013
    Applicant: CELERA CORPORATION
    Inventors: Yonghong LI, Hongjin HUANG
  • COLON CANCER TARGETS AND USES THEREOF
    Publication number: 20130067608
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: August 16, 2012
    Publication date: March 14, 2013
    Applicant: CELERA CORPORATION
    Inventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFERY
  • GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20130058914
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: February 28, 2012
    Publication date: March 7, 2013
    Applicant: CELERA CORPORATION
    Inventors: Olga IAKOUBOVA, James DEVLIN, Charles ROWLAND, Carmen TONG
  • GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20130045198
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: June 25, 2012
    Publication date: February 21, 2013
    Applicants: LEIDEN UNIVERSITY MEDICAL CENTER (LUMC), ACTING ON BEHALF OF ACADEMIC HOSPITAL LEIDEN (AZL), CELERA CORPORATION
    Inventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
  • GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF
    Publication number: 20130030051
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: June 1, 2012
    Publication date: January 31, 2013
    Applicants: UNIVERSITY OF TEXAS BOARD OF REGENTS, CELERA CORPORATION
    Inventors: Dov SHIFFMAN, James J. DEVLIN, Judy Z. LOUIE, Eric BOERWINKLE